Details for New Drug Application (NDA): 211212
✉ Email this page to a colleague
The generic ingredient in SIROLIMUS is sirolimus. There are twenty-one drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the sirolimus profile page.
Pharmacology for NDA: 211212
Mechanism of Action | Protein Kinase Inhibitors mTOR Inhibitors |
Physiological Effect | Decreased Immunologic Activity |
Medical Subject Heading (MeSH) Categories for 211212
Suppliers and Packaging for NDA: 211212
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
SIROLIMUS | sirolimus | SOLUTION;ORAL | 211212 | ANDA | Amneal Pharmaceuticals NY LLC | 69238-1594 | 69238-1594-3 | 1 CARTON in 1 KIT (69238-1594-3) / 1 BOTTLE, GLASS in 1 CARTON (69238-1594-6) / 60 mL in 1 BOTTLE, GLASS |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;ORAL | Strength | 1MG/ML | ||||
Approval Date: | Oct 18, 2019 | TE: | AA | RLD: | No |
Complete Access Available with Subscription